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Pier A. SerraAmperometric polymer/enzyme composite (PEC) biosensors, incorporating a
poly(o-phenylenediamine) ultra-thin permselective barrier, possess a variety
of characteristics that make them suitable for monitoring brain energy and
neurotransmitter dynamics in vivo. This review highlights PEC sensitivity and
selectivity parameters, which allow development of the basic design in a
systematic way in order to improve their performance and to diversify the
analyte range of these novel probes of brain function.
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781. Introduction
Understanding the mechanisms underly-
ing the functioning of the human brain
stands at the forefront of modern sci-
ence. Behavior, feelings, thoughts and
even consciousness itself may reflect the
interplay of its electrical and chemical
pathways. Clinical intervention in neu-
rological disorders is usually achieved
using chemical agents that act on neu-
romediator-related sites, suggesting that
intercellular chemical signaling plays a
major role in determining the properties
of neural networks. However, measuring
real-time chemical events in the living
brain is a supreme technical challenge,
even in animal models, and involves
many biocompatibility issues. A growing
number of analytical methodologies are
being developed, including sampling
[1,2], spectroscopic [3] and electro-
chemical [4–6], to study neurochemical
dynamics in the intact brain. One such0165-9936/$ - see front matter ª 2007 Elsevset of techniques involves the in-situ
detection of substances in brain extra-
cellular fluid (ECF) using implanted bio-
sensors.
Electrochemical biosensors exploit the
specificity of a biological component,
usually an enzyme immobilized on the
electrode [7–10], to provide sensitivity to a
target analyte. The chemical specificity
can be very high, even to the level of
stereoselectivity (e.g., the use of L-gluta-
mate oxidase (GluOx) in the design of
amperometric biosensors to detect neuro-
transmitter L-glutamate [11,12]).
However, the remarkable specificity of
enzyme-based amperometric biosensors
can be seriously undermined by interfer-
ence from electroactive species present in
the target medium, compromising the
selectivity of the device. This problem is
particularly pronounced for biosensors
implanted in biological tissues for real-
time monitoring [9,10,13,14], because
separation techniques cannot be exploited
to eliminate the interference, as is the
case for on-line microdialysis approaches
to in-vivo monitoring [8,15–17]. Despite
this drawback, considerable efforts have
been made over the past two decades to
overcome issues of in-vivo biosensor sen-
sitivity, selectivity and stability, mainly
because of the significant benefits of
biosensor monitoring: small probe size,
minimizing tissue damage [18–20]; and
high time resolution, allowing real-time
correlation with animal behavior
[8,10,13,21].ier Ltd. All rights reserved. doi:10.1016/j.trac.2007.11.008
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Biosensors are powerful analytical tools whose range of
applications in medical diagnostics [22], food-quality
control [23] and environmental monitoring [24] is
rapidly expanding. The design of an electrochemical
biosensor is predicated first on the target analyte and the
choice of appropriate biological element (e.g., L-gluta-
mate detection has been achieved using either glutamate
receptor ion channels [22], glutamate oxidase [25] or
glutamate dehydrogenase [26], and the respective elec-
trochemical steps can be very different [22]).
However, the vast majority of enzyme-based ampero-
metric biosensors exploit the biocatalytic oxidation of
analyte, using oxidase enzymes containing the pros-
thetic group, flavin adenine dinucleotide (FAD). Despite
this common foundation, a wide range of oxidase-based
devices have been designed to make use of different
signal-transduction mechanisms and diverse selectivity
strategies [7,9,10,22,26–29].
Another key factor shaping biosensor design is the
nature of the intended application matrix [10,24] (e.g.,
devices for monitoring analyte-concentration dynamics
in vivo must be biocompatible over the time course of the
implantation, both in terms of tissue effects on sensor
functionality, and physiological reaction to the probe
[20,30,31]). As well as possessing the appropriate level
of biocompatibility, implantable oxidase-based biosen-
sors must also fulfill the following minimum criteria for
reliable analyte monitoring:
 appropriate size and geometry [32,33];
 good sensitivity to the enzyme substrate [34];
 effective rejection of electroactive interference [35,36];
and,
 low sensitivity to changes in pO2 over the range of sub-
strate and oxygen concentrations relevant to the in-
tended application [11,37].
Even different tissues present distinct challenges. For
example, biosensors designed to monitor glucose in
blood or subcutaneous fat in vivo need a significantly
greater oxygen tolerance compared to devices for mon-
itoring brain ECF [38], because glucose levels are an
order of magnitude higher in these peripheral tissues
than in brain ECF [39].
Within these restrictions, a number of biosensor
designs have been developed and applied to monitor
concentration dynamics of specific brain analytes in vivo.
Among the first to be reported were those based on
organic conducting salt tetrathiafulvalene tetracyano-
quinodimethane (TTF-TCNQ) [40,41]. Although initially
thought to involve direct electron transfer between the
FAD center and this novel conducting surface, there is
now evidence that signal generation is mediated by
TCNQ from the electrode material [42,43]. It is inter-
esting to note that one of these seminal studies applied
the concept of a blank sensor (one containing all thedesign elements of the biosensor, but omitting the en-
zyme) implanted beside the biosensor in order to mini-
mize electroactive interference, using subtraction. This
strategy was necessary because interference by ascorbic
acid (AA, archetypal electroactive species that contam-
inates biosensor signals in vivo) can occur even at the
low anodic potentials used for this class of biosensor
[40,44]. The use of blank sensors coupled with biosen-
sors in difference mode is now seen as a vital component
of reliable brain monitoring [33,35,45–50], although
the use of a blank sensor does not mitigate the problem
of oxygen dependence of oxidase-generated signals.
A more common design of biosensor used for analysis
of brain systems (including brain slices in vitro and intact
tissue in vivo) incorporates redox hydrogels (e.g., osmium
poly(vinyl pyridine) redox polymer [51–53]), and this
biosensor design has also been implanted in peripheral
tissues [54]. The Os-gel-HRP provides mediated electron
transfer between the horseradish peroxidase, which
reacts with the H2O2 generated according to Reactions 1
and 2, and the electrode operating at mild cathodic
applied potentials [35]. These devices may also include
ascorbic acid oxidase and Nafion to reduce further
interference by AA.
Neurochemical studies in vivo, using these probes,
have been limited to acute implantation in anesthetized
preparations, and it is unclear at present whether this
class of biosensor is stable enough to allow long-term
brain monitoring in freely-behaving animals. The pres-
ence of anesthetic is an important issue for in-vivo
monitoring studies because different, and sometimes
opposite, effects on neurochemical dynamics have been
observed in the presence of anesthesia [10]. Thus, for
example, it is unwise to test the glutamate/ascorbate
heteroexchange hypothesis in chloral hydrate anesthe-
tized rats, using this class of biosensor [50], when it has
been demonstrated explicitly that chloral hydrate blocks
this exchange [55].
A design, which has recently been implanted suc-
cessfully for chronic recording in the brain of unanes-
thetized animals, exploits the anion-rejecting properties
of Nafion as the main strategy for reducing electroactive
interference at a ceramic-based biosensor [4,56], in
addition to a blank or sentinel electrode to increase
further the selectivity of the detection system [33,49].
The biosensor signal is generated by direct oxidation of
H2O2 on the electrode surface (Reactions 1–3) at a rel-
atively high applied anodic potential. Studies carried out
over seven days showed that there was little loss of the
sensitivity of the implanted differential device [33],
which indicates a promising future for this approach.
However, an issue that needs to be addressed before
widespread applications are undertaken is the oxygen
dependence of these biosensors, which has yet to be
reported. A variation on this design, which incorporates
additional polymer layers deposited over a platinumhttp://www.elsevier.com/locate/trac 79
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glucose [57], lactate [58] and glutamate [48].
The use of poly-ortho-phenylenediamine (PPD) as a
permselective membrane in the fabrication of implant-
able sensors and biosensors has been reported by a
number of laboratories [59–64]. Indeed, PPD has been
used in the construction of biosensors for a range ana-
lytes in different target media [63,65–71]. PPD can be
deposited electrochemically from o-phenylenediamine
(oPD) solutions at neutral pH to produce a thin, self-
sealing, insulating polymer on the electrode surface [69].
Film-thickness estimations for PPD generated under
these conditions are typically in the region of 10–30 nm
[69,72–74]. As well as possessing excellent interference-
rejection characteristics, PPD also serves as a method of
immobilizing enzymes and protects the electrode surface
from fouling [39,70], making it ideal for biosensor
applications in vivo [10]. The signal in this design is also
generated by the direct oxidation of H2O2 on the elec-
trode surface (Reactions 1–3) at relatively high applied
anodic potentials. A main advantage of PPD-based glu-
cose biosensors is their stability, even during ampero-
metric recording over days in freely behaving animals
[39,63,75,76]. In addition, the pO2 dependence of both
glucose- [38,63] and glutamate- [11,32,77] detecting
forms of these biosensors has been quantified in detail,Figure 1. The effects of electrode geometry on the glucose response of GOx
using cylinder (C, ) and disk (D, o) based devices of the type where the G
schematic on the right). Points are means ± SEM of current densities; cu
(R2 > 0.99). The enzyme loading density (Equation 11) is much greater fo
deposition compared with cylinders [38]. However, the mean apparent K
two designs: 15 ± 2 mM (n = 21); 15 ± 1 mM (n = 4); p > 0.94 [38]. Inset:
GOx/PPD configuration, showing the regression line with R2 = 0.995 and
are adapted from [38].
80 http://www.elsevier.com/locate/tracand shown to be adequate for brain monitoring (see
Section 6 below). Thus, although each design of bio-
sensor for brain monitoring has a key advantage, such
as the small cross-section of Os/gel/HRP-based carbon-
fiber electrodes [53,78] and the self-referencing
capability of the ceramic-based devices [49], the overall
long-term stability and oxygen tolerance of PPD-based
biosensors make them an attractive choice for further
development [11,65,79–82].
Here, we review the design of biosensors based on PPD
polymer/enzyme composite (PEC) permselective layers
for in-vivo neurochemical monitoring, with particular
emphasis on the usefulness of biosensor sensitivity and
selectivity parameters.3. PEC-biosensor notation
To allow functionality in the electrochemically hostile
environment of living brain tissue, implantable biosen-
sors often contain a variety of components to enhance
their sensitivity, selectivity and stability. These agents
are laid down in an order that depends on their intended
role, and so, in defining a systematic notation, this order
must be clear. The nomenclature employed here uses a
slash to indicate consecutive layering from left to right,/PPD-based biosensors, illustrated by glucose calibrations performed
Ox was adsorbed on the Pt before electropolymerization of PPD (see
rves were generated using non-linear regression and Equation (7a)
r the disk biosensors due to more efficient dip-evaporation enzyme
M value for glucose, KM(G), was not significantly different for these
Part of the linear region glucose response (Equation 10) for the PtC/
using the same axis units as the main graph. Plots and schematic
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rated by a hyphen. For example: Pt/GOx/PPD represents
glucose oxidase (GOx) deposited on Pt (normally by dip
evaporation [77,83]) followed by electropolymerization
of PPD (see Fig. 1); Pt/PPD/GOx indicates GOx deposited
over electropolymerized PPD; and Pt/GOx-PPD signifies
the co-deposition of enzyme and polymer by including
GOx in the monomer solution. This notation is quite
flexible and, where necessary, allows for such details as:
the geometry of the electrode (e.g., disks (D) or cylinders
(C) that can significantly affect biosensor performance
[11,77,84] (see Fig. 1)); the number of dip coatings
applied (four in the following example); and, the stock-
solution concentration of the agent deposited (e.g., 200
U/mL): PtD/GOx(200U)4/PPD.4. Enzyme-related biosensor parameters
A number of sophisticated mathematical models of the
behavior of enzymes in membranes have been described
[85,86]. These complex analyses are often needed to
understand and to optimize the behavior of thick and/or
conducting layers [87]. However, a recent study has
shown that substrate diffusion is not limiting for PPD
layers incorporating enzymes [88], due to their ultra-
thin nature (10-30 nm [69,72,74]). The basic Michaelis-
Menten enzyme parameters used here therefore provide
more readily accessible insights into factors affecting the
responsiveness of biosensors fabricated from the insu-
lating form of PPD, and avoid the use of more complex
analyses, such as those involving the Thiele modulus
[89].
For oxidase enzyme (E) with FAD as prosthetic group,
the catalytic conversion of substrate (S) and co-substrate
(O2) to products (P) and H2O2 can be written as Reac-
tions (1)–(3):
Sþ E=FAD ! Pþ E=FADH2 ð1Þ
E=FADH2 þ O2 ! E=FADþ H2O2 ð2Þ
H2O2 ! O2 þ 2Hþ þ 2e ð3Þ
The two-substrate form of the Michaelis-Menten equa-
tion for the overall rate of reaction, m, is given by
Equation (4) [89,90]:
m ¼ mmax
1þ KMðSÞ=½S þ KMðO2Þ=½O2 ð4Þ
If the concentration of the co-substrate is large and
constant, Equation (4) reduces to:
m ¼ m
0
max
1þ KMðSÞ=½S ð5Þ
Equation (5) represents the rate of product formation,
which in this case reflects the rate of H2O2 generation.
The H2O2 generated in the enzyme layer is the species
detected at the electrode surface, but its bulk concen-tration is zero; it is the flux of H2O2 from the immobilized
enzyme to the conducting surface that determines the
current. Converting the rate (Equation (5)) to current
(Equation (6)) is achieved by multiplying both sides by
AazF, where a is the fraction of the flux that is oxidized
on the electrode of geometric area, A (some H2O2 is lost
to the bulk [76]). Consistent with this analysis, many
biosensor designs respond hyperbolically to the bulk
concentration of enzyme substrate, and m0max (Equation
(5)) is related to Imax (Equation (6)) through the AazF
term. The value of KM, the concentration of substrate
that yields mmax/2, does not change with this conversion.
When comparing biosensors of different sizes, the
response (IS) can be normalized to current density (JS,
Equation (7a)) by dividing by area, A. Nonlinear
regression analysis of JS vs. [S] provides the basic
response parameters: Jmax, KM(S) and R
2. Alternatively, if
the concentration of S is fixed and O2 levels are changed,
then Equation (7b) can be used to analyze the oxygen
dependence of the signal [32,63], where J 0max is the
maximum (plateau) response for a particular concen-
tration of S, and KM(O2) is the apparent Michaelis
constant for oxygen.
IS ¼ Imax
1þ KMðSÞ=½S ð6Þ
JS ¼
Jmax
1þ KMðSÞ=½S ð7aÞ
JS ¼
J=max
1þ KMðO2Þ=½O2 ð7bÞ
The current density for the biosensor response to S, JS,
is a measure of the overall rate of the enzyme reaction,
and Jmax is the JS value at enzyme saturation. Different
values of Jmax, determined under the same conditions,
reflect differences in the activity of enzyme on the surface
(k2[E]; see Reaction (8)) [38], provided the sensitivity of
the electrode to H2O2 (Reaction (3)) does not vary much,
as is the case for many of the PPD-modified Pt cylinders
and disks used in brain monitoring [10,63,76].
The Michaelis constant, KM, is defined in terms of the
rate constants for the generalized reactions (Reaction
(8)) describing the conversion of substrate to products,
catalyzed by the enzyme (see Equation (9)). However,
when Equation (7a) is used to approximate the two-
substrate case, KM is more complex and contains
co-substrate terms. KM is then the apparent Michaelis
constant and phenomenologically defines the concen-
tration of substrate that gives half the Jmax response (see
Fig. 1). Thus, changes in KM are sensitive to the binding
constant, k1, and have been interpreted in terms of
barriers to substrate/enzyme binding [70,91], as well as
changes in oxygen demand [11,38,77,92]. When com-
paring biosensor parameters based on different enzymes
(e.g., GOx and GluOx (L-glutamate oxidase)), it may be
necessary to specify the enzyme substrate (e.g., KM(G) vs.http://www.elsevier.com/locate/trac 81
Figure 2. Example of the effects of Jmax and KM on the linear region
slope (LRS). Jmax was varied by controlling enzyme loading, and
Jmax, KM and the LRS measured experimentally (see Fig. 1) in the
presence and absence of polycationic polyethyleneimine (PEI) in
the PEC layer. Section of the scatter plots and linear regression
analyses for the Glu calibration linear region slope (LRS) versus Jmax
(Equation 10) for four biosensor designs fabricated by depositing
the polymer/enzyme composite GluOx/PPD on either PtC (filled
circles, n = 55), PtD (open circles, n = 61), PtC/PEI (filled triangles,
n = 27) or PtD/PEI (open triangles, n = 20). On bare Pt at low GluOx
loading (small Jmax), i.e., for PtC-based biosensors, there is a system-
atic increase in LRS with Jmax (slope = 1.3 ± 0.2, R
2 = 0.54,
p < 0.0001, n = 55). On bare Pt at higher GluOx loading, i.e., for
the PtD-based devices, there is no change in LRS with Jmax
(slope = 0.01 ± 0.02, R2 = 0.003, p > 0.65, n = 61). When PEI was
incorporated into the PEC layer, there was a systematic increase
in LRS with Jmax for both cylinders and disks (combined
slope = 1.2 ± 0.1, R2 = 0.49, p < 0.0001, n = 47). Thus, PEI led to
convergence of the responses for the two geometries. Plots and
analysis are adapted from [11].
Trends Trends in Analytical Chemistry, Vol. 27, No. 1, 2008KM(Glu)). When analyzing the influence of co-substrate
(O2) on the biosensor response, KM(O2) and KM(S) must
be distinguished [11,77].
Eþ S k1
k1
ES!k2 Eþ P ð8Þ
KM ¼ k1 þ k2
k1
ð9Þ
The apparent Michaelis constant for S is also useful
for defining the range of linear response to S (up to
1/2KM), as well as the slope in the linear region (LRS),
that is, LRS  Jmax/KM; see Equation (10).
Lt½S!0JS ¼
Jmax
1þ KM=½S ¼
Jmax½S
½S þ KM 
Jmax
KM
½S ð10Þ
Biosensors are usually designed to operate in real
applications within their linear region response to ana-
lyte, which is generally considered to extend as far as
KM/2. For biosensors incorporating GluOx, intended to
detect low levels of Glu in biological samples, a critical
property is high sensitivity in the linear region, whereas
the range of linearity in not a problem. Since
LRS  Jmax/KM (Equation (10)), increasing enzyme
loading is a common strategy in the quest for increased
LRS. However, the plot of LRS versus Jmax in Fig. 2
shows that the experimentally measured LRS does
not increase with Jmax for PtD/GluOx/PPD biosensors
because there is a corresponding increase in KM(Glu) for
this design due to electrostatic repulsion between the
anionic Glu analyte and the high polyanionic enzyme
density on these disk surfaces [84]. Neutralization of this
repulsion by incorporating polycationic polyethylene-
imine (PEI) into the PEC matrix restored this valuable
correlation (Fig. 2), allowing significant increases in
LRS values [11].
The turnover of O2 in PEC membranes (Reaction (2))
depends on the rate at which substrate binds to the
enzyme (Reaction (1)) (i.e. on substrate concentration).
Glucose is an example of an analyte with relatively high
concentrations in brain ECF, so it is a useful model
system for quantifying PEC sensitivity to changes in ECF
pO2. Experiments over a range of glucose concentra-
tions, including 0.5, 2.5 and 10.0 mM glucose, were
performed in vitro, where the pO2 was controlled in a
sealed environment, and the Pt/GluOx/PPD signal
monitored as a function of dissolved oxygen concentra-
tion [38,63] (see Fig. 3). The smaller the value of KM(O2)
in Equation (7b), the lower the oxygen dependence be-
cause higher oxygen affinity leads to oxygen saturation
at lower pO2, thereby reducing biosensor dependency at
higher pO2 levels. As predicted, O2 dependence became
more acute at higher glucose concentrations. For
10-mM glucose, a level not much greater than the
normoglycemic value in human blood [93] and less than
that observed under hyperglycemic diabetic conditions
[94], the O2 dependence was close to maximal (near-82 http://www.elsevier.com/locate/traclinear biosensor response to pO2) with a Km(O2) = 150
lM [38]. The Pt/PPD/GOx sensor design would therefore
not be suitable for monitoring blood glucose in vivo.
Fig. 3 also shows the glucose-O2 correlation plot for
0.5-mM glucose; the plot was hyperbolic, consistent with
Equation (7b), with R2 > 0.997, and values of Km(O2) in
the range 5–10 lM. The 0.5-mM glucose current
therefore displayed a low insensitivity to changes in O2
levels at average brain ECF levels of O2 (40 lM O2).
These in-vitro results suggest that Pt/PPD/GOx electrodes
might be suitable for brain monitoring, where the esti-
mated glucose level is much lower than that in blood.
Indeed, ECF glucose has been determined to be an order
of magnitude lower than blood levels by both quantita-
tive microdialysis (350 ± 16 lM [39]) and biosensor
studies (300–400 lM [95]) in the striatum of the awake
rat. We discuss the experimental oxygen dependence of
PEC-based biosensors in vivo in Section 6 below.
When the biosensor incorporates a component that
significantly affects the sensitivity of the surface to H2O2
(e.g., Nafion or lipid phosphatidylethanolamine (PEA)),
then variations in Jmax across sensor populations may be
due to changes in either enzyme activity or H2O2
Figure 3. Increase in oxygen dependence at higher concentrations of substrate for Pt/GOx/PPD biosensors in vitro. Examples of averaged
normalized glucose-oxygen correlation plots for three concentrations of glucose (filled circle, 0.5 mM, n = 3; open circle, 2.5 mM, n = 7; triangle,
10 mM, n = 6) studied over the relevant range of O2 concentration (N2 saturation to air saturation) showing the increased sensitivity of the bio-
sensor signal to solution pO2 as the concentration of glucose is increased [38,63]. The non-linear regression plots shown were obtained using
Equation (7b). Inset. The effect of systemic administration of the carbonic anhydrase inhibitor (Diamox, 50 mg/kg, i.p.) on the O2 and glucose
signals monitored simultaneously in vivo in rat brain striatum. Comparison of the O2 current (black, recorded using DPA with a carbon paste
electrode, CPE, in the left striatum) and glucose signal (grey, detected using amperometry at +700 mV with a Pt/GOx-PPD electrode in the right
striatum) illustrates that O2 availability does not impact significantly on glucose monitoring in brain ECF in vivo, where baseline glucose levels
are in the region of 0.5 mM [39]. Plots are adapted from [63].
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on two factors: the density of active enzyme molecules
on the surface (active enzyme loading, [E]); and, the
value of the catalytic rate constant, k2 (Reaction (8)).
Thus, enzyme activity is k2[E], and these two terms are
rarely separable, especially for implantable microelec-
trodes where dip evaporation is used to deposit enzyme
on the biosensor surface (i.e. [E] is not known indepen-
dently). A useful approximation to the effective activity
of surface enzyme is the parameter [E]act, defined in
Equation (11), where slope(HP) is the calibration slope
for H2O2 at the biosensor. Certainly, variations in [E]act
determined under the same conditions will reflect
changes in k2[E], which in turn often arise from changes
in [E] [84].
½Eact ¼
Jmax
slopeðHPÞ ð11Þ
BE% ¼ slopeðSÞ  100%
slopeðHPÞ ð11aÞ
An analogous, and possibly more useful, parameter,
which also normalizes the biosensor response with
respect to H2O2 sensitivity, is biosensor efficiency (BE%)
(see Equation (11a), where slope(S) is the LRS for enzyme
substrate). In theory, the absolute maximum value of
BE% should be 100% if the surface is saturated with
enzyme, all the H2O2 produced by the enzyme is electro-
oxidized on the surface, and the diffusion coefficients of S(DS) and H2O2 are equal. Since DS will always be less than
that for H2O2 (1.0 · 105 cm2/s) and some H2O2 is lost
to the bulk even in quiescent solution [76], then
(BE%)max < 100%. An empirical maximum appears to be
close to 60% [84], which is consistent with these factors.
Two additional parameters related to biosensor re-
sponse to substrate, S, are useful. Response times can be
recorded in constantly stirred solution, using a data-
acquisition rate of >10 Hz [32]. A t90% parameter has
been defined as the time taken for the analyte response
to reach 90% of its maximum value from the start
(<10%) of the current upswing, and is similar to defi-
nitions used elsewhere [4,50,96]. The limit of detection
(LOD) of S is usually determined using the widely applied
criterion of three times the SD of the baseline. Response
time and LOD are particularly crucial when designing
biosensors to monitor fast transients in brain neuro-
transmitters whose ECF levels are invariably low (e.g.,
L-glutamate, Glu). PEC-based devices (e.g., Pt/GluOx/PPD)
show good behavior in these respects, with t90% values of
3 s (just 1 s slower than to bulk H2O2) and an LOD of
<0.5 lM Glu [32,83].5. Polymer-related biosensor parameters
The main analytical parameters of the surface polymer
are related tohttp://www.elsevier.com/locate/trac 83
Figure 4. The calibration profile obtained by plotting steady-state
responses vs. AA concentration for Pt/PPD electrodes. Because of
the non-linearity of the AA response at these electrodes, it is neces-
sary to quantify the response in a number of ways. Firstly, the max-
imum current response, Imax and the concentration at which Imax
occurs, Cmax. This parameter gives a good indication of the appro-
priate application of the sensors; for example, AA is present in tis-
sues at concentrations ranging from 50 lM in blood to 500 lM in
brain ECF. Thirdly, the current at 1 mM AA (generally the plateau
region), Ilim, which serves for comparisons of the absolute AA
blocking ability of different polymers. Lastly, the current associated
with the concentration change from 0.5 mM to 1 mM (i.e., equiv-
alent to doubling brain ECF levels), DI, an even better indication of
the interference blocking ability of the polymer in neurochemical
analysis in vivo. Plot are adapted from [74].
Trends Trends in Analytical Chemistry, Vol. 27, No. 1, 2008(i) the sensitivity of the sensor to the target analyte
and the electroactive enzyme-transducer molecule
(H2O2; Reactions (1)–(3)); and,
(ii) its ability to reject interference species, especially
ascorbic acid (AA).
The starting point for determining these properties is
the sensitivity to H2O2 and AA at the bare metal. First,
the current-density responses of AA at bare microdisks
and cylinders are the same, as are those of H2O2, indi-
cating that subtle differences in diffusion profiles are not
significant in this context [65,97]. A direct comparison
of the amperometric sensitivity of pure Pt and Pt-Ir has
also been carried out [65,98]. A small loss of H2O2
sensitivity for the alloy compared with the pure metal
was observed, presumably due to the involvement of Pt
oxides in H2O2 electro-oxidation. The greater sensitivity
of both bare metal-electrode types for H2O2 compared
with AA is in line with diffusion-coefficient values for
the two analytes and diffusion-limited kinetics at the
operational applied potential (700 mV vs. SCE) [65].
2H2O2 ! 2H2Oþ O2 ð12Þ
Using a large population of wire electrodes, the
hypothesis that ultra-thin (10–30 nm [69,72,74]) elec-
trosynthesized PPD does not decrease the sensitivity of
Pt-Ir to H2O2 has been tested [65]. Surprising, the large
sample size revealed that PPD-modified Pt-Ir showed a
small, but statistically significant, increase in the H2O2
calibration slope (189 ± 10 lA/cm2/mM, n = 51) com-
pared with the bare metal (171 ± 6 lA/cm2/mM,
n = 51, p = 0.05 for a paired t-test). One possible expla-
nation for the unexpected small increase in the efficiency
of the electrochemical H2O2 oxidation on the coated
metal is that PPD inhibits the H2O2 disproportionation
reaction (Reaction (12)) at the electrode surface, the
extent of which varies with electrode condition. How-
ever, it is clear that the basic Pt-Ir/PPD design displays
near-optimal H2O2 sensitivity, so that the only effective
way to improve selectivity significantly is to increase
interference blocking by the polymer layer. The more
robust Pt-Ir working electrodes are therefore generally
used for implantable biosensors in vivo, and normally
designated as Pt for simplicity of notation. The perme-
ability of the PEC layer to H2O2 can therefore be defined
as in Equation (13), and is normally about 100 ± 10%
for the basic Pt/Ox/PPD designs [65,97,99].
PðHPÞ% ¼ slopeðHPÞ at Pt=PEC  100%
slopeðHPÞ at Pt ð13Þ
An unusual property of PPD-based PEC layers is their
ability to reject AA more efficiently at higher AA con-
centrations (Fig. 4). Indeed, at extremely low levels of
AA, the response of Pt/PPD electrodes is similar to bare
Pt; however, even at 10-lM AA, AA sensitivity (IAA/
[AA]) is considerably lower than that at bare metal [99].
AA, and/or its oxidation product, trapped in the polymer84 http://www.elsevier.com/locate/tracmatrix therefore appears to cooperate efficiently with
PPD in a form of ‘‘self blocking’’ [74,99], so that, by
concentrations in the 100-lM region, the AA response is
essentially flat (Fig. 4). Because of this non-linear
behavior of AA at Pt/PEC electrodes, the 1-mM value
(plateau response, Ilim; see Fig. 4) is used in the corre-
sponding definition of AA permeability, P(AA)% (Equa-
tion (14)).
PðAAÞ% ¼ IlimðAAÞ at Pt=PEC  100%
slopeðAAÞ at Pt ð14Þ
The main focus in using P(HP)% is to maintain its
value as close to 100% as possible (see above). The
finding that values of P(HP)% greater than 100% have
been observed indicates that this is not a true perme-
ability, possibly due to complications (e.g., Reaction
(12)). However, P(AA)% is very small (0.2% [65,74])
and probably reflects the poor ability of AA to permeate
the PEC layer. The problems with interpreting P(HP)%
indicate that the permselectivity, SP%, defined by Equa-
tion (15), is probably not the most useful parameter for
quantifying PEC selectivity.
SP% ¼ PðAAÞ%  100%
PðHPÞ% ð15Þ
Instead, the equimolar selectivity, S%, defined by
Equation (16), is a good index of the relative sensitivities
Trends in Analytical Chemistry, Vol. 27, No. 1, 2008 Trendsof the PEC-coated metal to the two analytes. Because S%
represents a percentage interference, the smaller the
value, the more suitable the polymer is for biosensor
applications, and values as low as 0.2% have been
reported for PPD-based devices [65,74].
S% ¼ IlimðAAÞ at Pt=PEC  100%
slopeðHPÞ at Pt=PEC ð16Þ
However, the polymer composite can also affect the
behavior of the trapped enzyme [38,77]. Thus, although
S% is a good parameter for monitoring the effects of the
polymer layer on relative H2O2 and AA sensitivities, and
a good (low) value of S% is a prerequisite for a successful
biosensor design, it is not sufficient. Having established a
good S% value, it is necessary to quantify the effects of
the polymer composite on enabling the production of
H2O2 by the enzyme. The biosensor LRS for substrate is
the best measure of the biosensors analytical signal
strength (see Equation (10)), incorporating both its
ability to generate H2O2 enzymatically and its electro-
chemical sensitivity to this molecule. Thus, we might
define the equimolar substrate selectivity, SS%, by
Equation (17), which will be intrinsically larger (worse)
than S% due to factors discussed above.
SS% ¼ IlimðAAÞ at Pt=PEC  100%
LRS at Pt=PEC
ð17Þ
Finally, the substrate concentration in the ECF needs
to be taken into account by defining SS(ECF)% as Equa-
tion (18), where IS(ECF) is the current for the estimated
average baseline concentration of target analyte, S, ob-Figure 5. The response of a Pt/GOx-PPD electrode implanted in the striatu
sensor implantation. Injection of insulin (15 U/kg, i.p. – see Inset) caused a d
of food (see Inset) [75,76]. Plots are adapted from [76].tained by scaling the LRS. SS(ECF)% is a measure of the
contributions of AA and S to the baseline biosensor re-
sponse recorded in the ECF.
SSðECFÞ% ¼ IlimðAAÞ at Pt=PEC  100%
ISðECFÞ at Pt=PEC ð18Þ
A useful variation on SS(ECF)% is SS(ECFD)%, which is
the substrate-selectivity parameter based on doubling
baseline ECF levels of both S and AA (Equation (19)).
The significance of DI(AA) can be seen in Fig. 4, and
IS(ECF) has the same value as for Equation (18). This
latter parameter provides a measure of the percentage
interference by AA in changes in the biosensor signal
recorded in brain ECF, and therefore represents a key
selectivity parameter for in vivo applications.
SSðECFDÞ% ¼ DIðAAÞatPt=PEC  100%
ISðECFÞatPt=PEC ð19Þ
It is not so important that some of these later selec-
tivity coefficients generate larger values than the more
common standard S% parameter. More critical is the
evolution of the value of the selectivity parameter of
choice with systematic fine tuning of the biosensor
design.
6. Brain monitoring with PEC-based biosensors
in vivo
The high baseline levels of glucose in brain ECF
(0.5 mM [39]), coupled with the excellent permselec-
tivity of PPD-based biosensors, have made it possible tom of a freely-moving fasting rat over a 80-min period, 12 days after
ecrease in the level of the signal which was reversed by the ingestion
http://www.elsevier.com/locate/trac 85
Figure 6. Effect of ascorbate injection (2 g/kg, i.p. – see Inset) on the amperometric response of a carbon paste electrode (CPE) at 200 mV and a
Pt/GOx-PPD electrode at 700 mV, implanted bilaterally in the striatum of the rat, 8 days after implantation. Plots are adapted from [76].
Trends Trends in Analytical Chemistry, Vol. 27, No. 1, 2008monitor physiologically and pharmacologically related
concentration dynamics of this energy metabolite in vivo
[39,61,63,75,76,100]. Many of these studies used
devices of the type Pt/GOx-PPD because these can be
fabricated in a one-step procedure by incorporating
enzyme in the monomer solution, in contrast to the
multiple dip-evaporation protocol for Pt/GOx/PPD sen-
sors. In addition, the comparable sensitivity to glucose of
these two designs has been demonstrated [83].
As outlined in Section 2, a main advantage of PPD-
based glucose biosensors is their stability, even during
amperometric recording over several days in freely
behaving animals [39,63,75,76]. Fig. 5 shows the
response of a Pt/GOx-PPD biosensor, which had been
implanted in rat-brain striatum 12 days previously, to
the systemic administration of insulin. The inset (Fig. 5)
shows that this hormone produced a sustained depres-
sion in brain-ECF-glucose levels, which could be reversed
by the ingestion of food (access to food had been
restricted for the previous 12 h). The effects of insulin on
brain-ECF glucose have been confirmed recently using a
PPD-based biosensor incorporating a ruthenium layer
[61], although the baseline observed in vivo with these
devices was not as stable as that recorded with Ru-free
PEC design (Fig. 5).
In addition to the PEC layer maintaining its sensitivity
to brain glucose, the permselective membrane is also
capable of rejecting AA interference after long periods
implanted in the tissue. Fig. 6 shows that systemic
administration of AA, at a dose that doubled brain-ECF
AA levels (detected with an implanted carbon-paste
electrode, CPE), had no significant effect on the Pt/GOx-
PPD biosensor signal (inset, bottom). A similar combi-86 http://www.elsevier.com/locate/tracnation of bilaterally implanted biosensor and CPE has
been used to confirm the in-vitro findings (see Fig. 3)
that, for physiologically relevant ECF concentrations of
glucose and oxygen, oxygen demand does not limit
biosensor functionality. Fig. 3 (inset) illustrates that
systemic injection of a carbonic anhydrase inhibitor
(Diamox), which significantly raised simultaneously
monitored brain ECF pO2, had no detectable effect on the
Pt/GOx-PPD signal [63].
Taken together, the literature reports on Pt/GOx-PPD
indicate that these biosensors possess sufficient glucose
sensitivity, selectivity and stability to monitor this energy
metabolite reliably in brain ECF over extended periods.
However, the challenge remains to be how to boost PEC
performance even further to allow the analogous Pt/
GluOx/PPD devices to monitor brain-ECF-Glu dynamics
at levels two orders of magnitude lower than those of
glucose. The incorporation of polycationic PEI into the
PEC design has provided an important step in that
direction by enhancing the Glu sensitivity significantly
(see Fig. 2). Preliminary results in vivo with these
PEI-modified biosensors indicate that long-term Glu
monitoring may soon be possible with further fine
turning of this design [45].Acknowledgements
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